New Drug-Radiation combo aims to stop early lung cancer in its tracks
NCT ID NCT07379398
First seen Feb 01, 2026 · Last updated Jun 19, 2026 · Updated 21 times
Summary
This phase 2 trial tests whether combining two immune-boosting antibodies (iparomlimab and tuvonralimab) with precise, high-dose radiation (SBRT) can better control early-stage non-small cell lung cancer. About 28 adults with stage I-IIB disease will receive the drug combination every 3 weeks for a year, starting shortly after their first radiation session. The main goal is to see how many patients remain cancer-free after one year.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Tianjin Medical University Cancer Institute and Hospital
Tianjin, Tianjin Municipality, 300000, China
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
iparomlimab and tuvonralimab (immune-boosting antibodies) plus stereotactic body radiation therapy (SBRT)
What this could lead to
If successful, this combination could improve control of early-stage lung cancer and reduce the chance of the cancer coming back after treatment.
What could go wrong
This is a small, early-phase trial with only 28 people, so results may not apply to everyone. Immune-related side effects and radiation risks are possible.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.